| 論文名 |
Antitumor activity of PEGylated biodegradable nanoparticles for sustained release of docetaxel in triple-negative breast cancer. |
| 著者 |
Giuseppe Palma
Claudia Conte
Antonio Barbieri
Sabrina Bimonte
Antonio Luciano
Domenica Rea
Francesca Ungaro
Pasquale Tirino
Fabiana Quaglia
Claudio Arra
|
| キーワード |
|
| 出版年月 |
1970年1月 |
| 発表先 |
Int J Pharm. 2014 Oct 1;473(1-2):55-63. doi: 10.1016/j.ijpharm.2014.06.058. Epub 2014 Jun 30. |
| WEBサイト |
|
| 論文概要（和文） |
トリプルネガティブ乳癌におけるドセタキセルの徐放のためのペグ化生分解性ナノ粒子の抗腫瘍活性 |
| 論文概要（英文） |
With the aim to find novel therapeutical approaches for triple-negative breast cancer (TNBC) treatment, we have developed a powder for i.v. injection based on cyclodextrins and docetaxel (DTX)-loaded polyethyleneglycol-poly(epsilon-caprolactone) nanoparticles (DTX-NPs). Nanoparticles are designed to concentrate at tumor level by enhanced permeability and retention effect and release drug cargo at a sustained rate in the blood and in tumor interstitium. DTX-NPs of around 70 nm, shielding proteins and allowing a sustained DTX release for about 30 days, were produced by melting sonication technique. DTX-NPs were associated to hydroxypropyl-β-cyclodextrin to give a powder for injection with excellent dispersibility and suitable for i.v. administration. DTX-NPs were as efficient as free DTX in inhibiting cell growth of MDA-MB231 cells, even at low concentrations, and displayed a comparable in vivo antitumor efficacy and better survival in a TNBC animal model as compared with DTX commercial formulation (Taxotere(?)). In conclusion, PEGylated biodegradable DTX-NPs highlighted their potential in the treatment of aggressive TNBC providing a foundation for future clinical studies. |
